Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.39 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.39 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.38 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19089669 | 0.88 | EGFR (0.49) | EGFRTNNI3KERBB2ERBB4ERBB3 | |
| SCHEMBL20548999 | 0.88 | EGFR (0.46) | EGFRTNNI3KCDK9ERBB3CCNT1 | |
| SCHEMBL19089423 | 0.80 | EGFR (0.44) | EGFRTNNI3KCDK9ERBB2ERBB3 | |
| SCHEMBL19089668 | 0.75 | EGFR (0.54) | EGFRKDR | |
| SCHEMBL19089505 | 0.74 | EGFR (0.56) | EGFRTNNI3KERBB2ERBB4ERBB3 | |
| SCHEMBL19089424 | 0.73 | KMT2A (0.43) | EGFRTNNI3KERBB3 | |
| SCHEMBL29373957 | 0.72 | ABCG2 (0.41) | EGFRTNNI3KCDK9ERBB3CDK4 | |
| SCHEMBL28688099 | 0.72 | ABCG2 (0.41) | EGFRTNNI3KCDK9ERBB3CDK4 | |
| SCHEMBL7777514 | 0.72 | TNNI3K (0.53) | EGFRTNNI3KKDRCDK4CDK2 | |
| SCHEMBL2205173 | 0.71 | KMT2A (0.55) | EGFRTNNI3KCDK9ERBB2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398939-B1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| EP-3398939-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | Ancureall Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | EGFR, ABL1, CSNK1A1 | EGFR 1/4885TNNI3K 111/4885CDK9 857/4885 |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | EGFR, ABL1, CSNK1A1 | EGFR 1/4885TNNI3K 111/4885CDK9 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.